[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339286-105":59,"doc-detail-339286-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","integrated-clinical-and-prognostic-analyses-of-mtorhippo-pathway-core-genes-in-hepatocellular-carcinoma","Integrated clinical and prognostic analyses of mTOR/Hippo pathway core genes in hepatocellular carcinoma","","Hepatocellular carcinoma (HCC) is a highly aggressive cancer worldwide, and growing evidence implicates mTOR and Hippo signaling as oncogenic drivers. Yet their prognostic relevance in HCC has remained uncertain. This study develops an mTOR/Hippo-based gene signature using a multiple-stage screening strategy, constructing a 12-gene model to estimate patient risk. Signature risk scores inversely associate with prognosis, and validation in independent cohorts confirms predictive performance. Multi-omics comparisons reveal molecular differences between high- and low-risk groups, including an immunosuppressive microenvironment in high-risk patients. The signature also predicts sensitivity to current chemotherapeutic drugs, providing a robust independent tool for survival prediction and supporting clinical therapeutic guidance.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrated-clinical-and-prognostic-analyses-of-mtorhippo-pathway-core-genes-in-hepatocellular-carcinoma/339286/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrated-clinical-and-prognostic-analyses-of-mtorhippo-pathway-core-genes-in-hepatocellular-carcinoma/339286.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the study on mTOR/Hippo genes in HCC?","Question",{"text":112,"@type":113},"To build and validate an mTOR/Hippo gene signature that can predict hepatocellular carcinoma prognosis and guide therapeutic decision-making.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the 12-gene signature constructed and validated?",{"text":117,"@type":113},"A multiple-stage strategy was used to screen candidate genes and generate a 12-gene model, then the signature was validated in an independent patient cohort to confirm its predictive power.",{"name":119,"@type":110,"acceptedAnswer":120},"What distinguishes high-risk from low-risk groups at the molecular level?",{"text":121,"@type":113},"High- and low-risk groups show molecular differences across genomic, transcriptomic, and protein-interaction levels, and immune infiltration results indicate an immunosuppressive state in the high-risk group.",{"name":123,"@type":110,"acceptedAnswer":124},"Can the gene signature predict responses to chemotherapy?",{"text":125,"@type":113},"Yes. The study reports that the signature can predict sensitivity to current chemotherapeutic drugs.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},339286,1791186409,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Journal of Physiology and Biochemistry (2024) 80:439–449  \n[https://doi.org/10.1007/s13105-024-01015-0](https://doi.org/10.1007/s13105-024-01015-0)  \nIntegrated clinical and prognostic analyses of mTOR/Hippo pathway core genes in hepatocellular carcinoma  \nTianhang Feng1 · Ping Chen2 · Tao Wang1 · Chunyou Lai1 · Yutong Yao1  \nReceived: 10 August 2023 / Accepted: 29 February 2024 / Published online: 12 March 2024 © The Author(s) 2024  \nAbstract  \nHepatocellular carcinoma (HCC) is one of the most aggressive and dismal cancers globally. Emerging evidence has established that mTOR and Hippo pathways are oncogenic drivers of HCC. However, the prognostic value of these pathways in HCC remains unclear. In this study, we aimed to develop a gene signature utilizing the mTOR/Hippo genes for HCC prognostication. A multiple stage strategy was employed to screen, and a 12-gene signature based on mTOR/Hippo pathways was constructed to predict the prognosis of HCC patients. The risk scores calculated by the signature were inversely correlated with patient prognosis. Validation of the signature in independent cohort confirmed its predictive power. Further analysis revealed molecular differences between high and low-risk groups at genomic, transcriptomic, and protein-interactive levels. Moreover, immune infiltration analysis revealed an immunosuppressive state in the high-risk group. Finally, the gene signature could predict the sensitivity to current chemotherapeutic drugs. This study demonstrated that combinatorial mTOR/ Hippo gene signature was a robust and independent prognostic tool for survival prediction of HCC. Our findings not only provide novel insights for the molecular understandings ofmTOR/Hippo pathways in HCC, but also have important clinical implications for guiding therapeutic strategies.  \nKeywords Hepatocellular carcinoma · mTOR · Hippo · Prognosis · Gene signature  \n\n| Tianhang Feng and Ping Chen contributed equally to this work. |\n| --- |\n| Key points\u003Cbr>• Developing a 12-gene signature on mTOR/Hippo pathways to predict HCC prognosis.\u003Cbr>• The signature risk scores were correlated with patient outcomes.\u003Cbr>• Exploration the molecular differences at genomic,\u003Cbr>transcriptomic, and protein levels.\u003Cbr>• The signature predicted chemotherapeutic sensitivity. Tianhang Feng and Ping Chen contributed equally to this work. |\n\n* Chunyou Lai [laichunyou2010@163.com](laichunyou2010@163.com)  \n* Yutong Yao [yaoyutong_meduestc@163.com](yaoyutong_meduestc@163.com)  \n1 Department of Hepatobiliary and Pancreatic Surgery, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China  \n2 Department of Laboratory Medicine, West China Second University Hospital, Sichuan University, Chengdu, China  \nIntroduction  \nHepatocellular carcinoma (HCC) is the most common typeof liver cancer and accounts for 75–90% of all liver cancers, causing over 600,000 deaths annually [24, 28] . Despite significant advancements in diagnosis and treatment, the 5-year survival rate of HCC patients remains low, with only ~ 18% of patients surviving beyond 5 years after diagnosis [22] . Although drugs like sorafenib and regorafenib have shown some effectiveness against advanced HCC, their overall impact on survival is limited [13, 17] . Actually, one of the major challenges in treating HCC is the tumor heterogeneity and high frequency of recurrence, which makes it difficult to predict the outcome and design effective treatments [7, 9] . Therefore, there is an urgent need for better predictive tools to identify patients at high risk of recurrence and poor outcomes, in order to develop more targeted and effective therapies.  \nConventional prognostic models for HCC rely on clinicopathological factors including tumor size, number of lesions, microvascular invasion, and cirrhosis, as well as the levels of certain biomarkers in serum [4, 14, 25] . However, these  \nprogno","cbCaisOWamsw7DjQ","https://ap.wps.com/l/cbCaisOWamsw7DjQ","pdf",1688931,11,"English","# Abstract\n# Introduction\n## Clinical need for better prognostic tools\n## Limitations of conventional prognostic models\n## Role and interplay of mTOR and Hippo pathways\n# Key points","[{\"question\":\"What is the main goal of the study on mTOR/Hippo genes in HCC?\",\"answer\":\"To build and validate an mTOR/Hippo gene signature that can predict hepatocellular carcinoma prognosis and guide therapeutic decision-making.\"},{\"question\":\"How was the 12-gene signature constructed and validated?\",\"answer\":\"A multiple-stage strategy was used to screen candidate genes and generate a 12-gene model, then the signature was validated in an independent patient cohort to confirm its predictive power.\"},{\"question\":\"What distinguishes high-risk from low-risk groups at the molecular level?\",\"answer\":\"High- and low-risk groups show molecular differences across genomic, transcriptomic, and protein-interaction levels, and immune infiltration results indicate an immunosuppressive state in the high-risk group.\"},{\"question\":\"Can the gene signature predict responses to chemotherapy?\",\"answer\":\"Yes. The study reports that the signature can predict sensitivity to current chemotherapeutic drugs.\"}]","Integrated clinical and prognostic analyses of mTOR/Hippo pathway core genes in hepatocellular carcinoma | PDF",1790029240,28,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5768cb9d6f7590049ed0a75fc983f0b.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86f62b71b6ac860433ca8772b3cd1b83.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf27f6b9af3128473802bb9d0d114b9d.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf9a848464fac985ff492cc896e73dcd.webp",980,1301]